Is biologic therapy the future of granuloma annulare treatment?

Dermatol Ther. 2022 Jan;35(1):e15188. doi: 10.1111/dth.15188. Epub 2021 Nov 14.

Abstract

Granuloma annulare (GA) is a benign inflammatory skin disease that presents with erythematous papules and annular plaques. The pathogenesis of GA remains unknown and may potentially involve type 1 T helper cell (Th1)-mediated delayed-type hypersensitivity reaction. GA is associated with many conditions such as malignancy, trauma, thyroid disease, diabetes mellitus, and viral infection. The role of biological treatment is under investigation. In this article, we present a case of GA development following systemic treatment of psoriatic arthritis in a 59-year-old patient; golimumab therapy resulted in the successful treatment of both psoriatic arthritis and GA. This is the first case report describing GA therapy using golimumab.

Keywords: biological treatment; golimumab; granuloma annulare.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Biological Therapy
  • Diabetes Mellitus*
  • Granuloma Annulare* / diagnosis
  • Granuloma Annulare* / drug therapy
  • Humans
  • Middle Aged
  • Th1 Cells